---

$89.31

-3.1600 ( -3.42% ) 1.1M

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2023-12-22	Sale	-350.00	Buller Richard E
2023-12-18	Sale	-5000.00	Dalvey David
2023-12-14	Sale	-2060.00	Dalvey David
2023-12-11	Sale	-5000.00	Dalvey David
2023-11-30	Sale	-250.00	Furcht Leo
2023-10-27	Sale	-350.00	Buller Richard E
2023-09-01	Sale	-350.00	Buller Richard E
2023-08-29	Sale	-21250.00	Hahne Vicky
2023-08-29	Sale	-21250.00	Laing Lance G.
2023-08-29	Sale	-180000.00	Sullivan Brian F.